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Background: We aimed to examine the prevalence of and modifiable factors associated with elevated C-reactive
Protein (CRP), a marker of inflammation, in men and women with newly diagnosed Type 2 Diabetes mellitus (DM)
in a population-based setting.
Methods: CRP was measured in 1,037 patients (57% male) with newly diagnosed Type 2 DM included in the
prospective nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project. We assessed the
prevalence of elevated CRP and calculated relative risks (RR) examining the association of CRP with lifestyle and
clinical factors by Poisson regression, stratified by gender. We used linear regression to examine the association of
CRP with other biomarkers.
Results: The median CRP value was 2.1 mg/L (interquartile range, 1.0 – 4.8 mg/L). In total, 405 out of the 1,037
Type 2 DM patients (40%) had elevated CRP levels (>3.0 mg/L). More women (46%) than men (34%) had elevated
CRP. Among women, a lower risk of elevated CRP was observed in patients receiving statins (adjusted RR (aRR) 0.7
(95% confidence interval (CI) 0.6-0.9)), whereas a higher risk was seen in patients with central obesity (aRR 2.3 (95%
CI 1.0-5.3)). For men, CRP was primarily elevated among patients with no regular physical activity (aRR 1.5 (95% CI
1.1-1.9)), previous cardiovascular disease (aRR1.5 (95% CI 1.2-1.9) and other comorbidity. For both genders, elevated
CRP was 1.4-fold increased in those with weight gain >30 kg since age 20 years. Sensitivity analyses showed
consistent results with the full analysis. The linear regression analysis conveyed an association between high CRP
and increased fasting blood glucose.
Conclusions: Among newly diagnosed Type 2 DM patients, 40% had elevated CRP levels. Important modifiable risk
factors for elevated CRP may vary by gender, and include low physical activity for men and central obesity and
absence of statin use for women.
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In patients with Type 2 diabetes mellitus (DM), the level
of systemic inflammation, measured by C-reactive pro-
tein (CRP), may be a predictor of cardiovascular disease
(CVD) and worse prognosis [1,2]. Thus, for prevention
purposes, early detection of elevated CRP levels and
identification of modifiable factors associated with this
condition are important [3]. Information regarding ele-
vated CRP levels and associated factors at the time of
Type 2 DM diagnosis in a population-based setting is
limited. In cross-sectional studies of the general popula-
tion, elevated levels of CRP are often found in older
people, in those with high Body Mass Index, and in less
physically active people [4,5]. Lower CRP levels have
been reported among individuals with regular alcohol
consumption and those under statin treatment [5,6]. We
thus aimed to examine the prevalence of and modifiable
factors associated with elevated CRP among newly diag-
nosed Type 2 DM patients included in the nationwide
Danish Centre for Strategic Research in Type 2 Diabetes
(DD2) cohort study. As CRP is higher in females than
males [7,8], we also wished to examine whether factors
associated with elevated CRP in Type 2 DM differed be-
tween genders.
Methods
We conducted this prevalence study using cross-
sectional baseline data from DD2, a nationwide cohort
study of newly diagnosed Type 2 DM patients enrolled
from the practices of general practitioners (GPs) and
hospital specialist outpatient clinics in Denmark since
November 2010 [9]. At enrolment into the study cohort
66% were on antidiabetic treatment [10], among the pa-
tients included in this current study 71% started within
one year prior to study start or after. The implementa-
tion and logistics of the DD2 project, patient enrollment,
and the DD2 biobank have been described previously
[11]. In brief, GPs or hospital physicians enter detailed
interview and clinical examination data into the DD2
database (questionnaire provided in [11]). Blood (fasting)
and urine samples are obtained from each patient, either
on the day of the interview or during a later visit.
Linkage of data among different Danish medical and
administrative registries is possible via a unique personal
identifier (CPR number) provided to each resident at
birth or upon immigration [12]. The CPR number
allowed data linking of the DD2 cohort with other Da-
nish registries.
Lifestyle -, clinical factors and biomarkers
From the DD2 database, we extracted data on age, gen-
der, high alcohol intake, regular physical activity, waist
circumference (central obesity) and weight gain since
age 20 years, as described in detail by Nielsen et al. [11].The complete hospital contact history of each parti-
cipant was obtained through linkage with the Danish
National Registry of Patients (DNRP), which covers
discharge records from all Danish hospitalizations since
1977 [13] and hospital outpatient visits since 1995.
Diagnoses in the DNRP are coded according to the
International Classification of Diseases (ICD), 8th revision
(ICD-8) codes until 1994 and 10th revision (ICD-10)
thereafter. From the DNRP, we obtained information on
patients’ major chronic disease diagnoses since 1977,
defined as those included in the Charlson Comorbidity
Index (CCI) [14]. Based on hospital diagnosis codes
(ICD-8 and ICD-10) for these conditions [15], we com-
puted a CCI score for each person, excluding diabetes.
We then defined three comorbidity levels: low (score
of 0), medium (score of 1–2), and high (score of 3+).
Diabetes was excluded from the CCI as it constituted
the index disease of our study population. We separately
ascertained previous diagnoses of any cardiovascular
disease.
Complete data on antihypertensive and hypolipidemic
treatment for each Type 2 DM patient were obtained
through linkage with the Danish National Database of
Reimbursed Prescriptions [16].
From the DD2 Biobank we also extracted information
on the following biomarkers: Alanine Transferase
(ALAT) levels, measured by the photometric method
using the COBAS-6000 analyser, Roche Diagnostics;
amylase levels, measured using an enzymatic colorimetric
method (Pancreas-α-amylase); C-peptide levels, measured
using the ADVIA Centaur C-Peptide assay (Siemens
Healthcare Diagnostics Ltd, Frimley, Camberley, UK);
and fasting blood glucose levels, analyzed using a en-
zymatic hexokinase method (Gluco-quant Glucose/HK,
Roche Diagnostics).
C-reactive protein (CRP)
From the DD2 biobank we extracted information on
CRP levels, which were measured in the first 1,037 Type
2 DM patients who enrolled in the DD2 project. The
particle-enhanced immunoturbidimetric method using
Tina-quant C-reactive Protein Gen.3 (Roche Diagnostics
GmbH, Mannheim, Germany), was used to measure
CRP, with the possibility of measuring CRP within the
limits of 0,3 - 350 mg/l; this is not a high-sensitivity
CRP measurement. Elevated CRP levels was classified as
CRP levels over >3.0 mg/L according to the guidelines
of the Centers for Disease Control and the American
Heart Association [17].
Patient registration and sample collection for the DD2
project have been approved by the National Committee
on Health Research Ethics (Denmark) (record number
S-20100082) and the Danish Data Protection Agency
(record number 2008-58-0035). After receiving detailed
Svensson et al. BMC Endocrine Disorders 2014, 14:74 Page 3 of 7
http://www.biomedcentral.com/1472-6823/14/74oral and written information approved by the National
Committee on Health Research Ethics (Denmark), pa-
tients volunteer to participate in the DD2 project and
sign a written informed consent document.
Statistical analysis
We calculated the median CRP value and examined the
number of Type 2 DM patients within pre-specified
groups defined in terms of demographic -, lifestyle-, and
clinical characteristics. The prevalence of elevated CRP
was calculated as the proportion of patients with a CRP
value > 3 mg/L.
In order to exclude patients with underlying condi-
tions such as infection, we also conducted two sub-
analyses, one restricted to individuals with CRP levels
≤10 mg/L, the second restricting to individuals not hos-
pitalized 14 days prior to entry into the study.
We calculated crude and adjusted relative risks (RR) of
elevated CRP and their corresponding 95% confidence
intervals (CI), comparing patients with and without dif-
ferent factors, stratified by gender. We used sequential
cumulative adjustment models in the Poisson regression
analyses with robust error variance, controlling first for
age; then central obesity. In the full model we adjusted
for age, central obesity, comorbidity level, physical activ-
ity, and high alcohol intake.
To examine the association of CRP levels with bio-
markers, measured as continuous variables, we per-
formed linear regression analysis. In all linear regression
analyses, a normal distribution was approximated by
log-transforming the variables. Multiple linear regression
analysis was used. In the first step we adjusted for age
and gender (Model 1); in the second step we adjusted
for age, gender, and waist circumference (Model 2); and
in the third model we adjusted for age, gender, waist cir-
cumference, ALAT, C-peptide, and fasting blood glucose
levels.
All analyses were performed using SAS version 9.2
(SAS Institute, Inc., Cary, North Carolina).
Results
In the 1,037 newly diagnosed Type 2 DM patients (43%
women, 57% men), the distribution of CRP levels was
skewed to the right, with a median value of 2.1 mg/L
(interquartile range, 1.0 – 4.8 mg/L), ranging from 0 to
69.8 mg/L. In total, 405 out of 1,037 patients (40%) had
elevated CRP levels (>3.0 mg/L), with more females
(46%) than males (34%) having elevated CRP. A CRP
level of 6 mg/L or more was observed in 20% of the pa-
tients, while 97 (9%) had a CRP level >10 mg/L.
Table 1 shows demographic, clinical, and lifestyle char-
acteristics according to CRP levels stratified by gender,
and the corresponding crude and fully adjusted relative
risks, with 95% CI (data not shown for the adjustedmodel with age alone, and age + central obesity, as there
were few differences between these models and the full
model).
For female patients, a lower risk of elevated CRP was
observed in patients receiving statins (adjusted relative
risk (aRR) 0.7 (95% confidence interval (CI) 0.6-0.9))
compared to patients not receiving statins, while a sub-
stantially higher risk was seen in patients with central
obesity (aRR 2.3 (95% CI 1.0-5.3)) compared to patients
without central obesity (Table 1).
For males, a higher risk of elevated CRP was observed
in particular in patients with no regular physical activity
(aRR 1.5 (95% CI 1.1-1.9)) compared to males with regu-
lar physical activity, and in those with previous cardio-
vascular disease (aRR 1.5 (95% CI 1.2-1.9) compared to
no cardiovascular disease. Additionally, higher risk was
observed in male patients with a moderate or high over-
all CCI score (aRR 1.5 (95% CI 1.2-1.9) for scores of 1-2
and 2.07 (95% CI 1.4-2.9) for scores of 3+) compared to
patients with a score of 0. Increased risk of elevated CRP
was also seen among males with central obesity (al-
though to a smaller extent than in females), and de-
creased risk was associated with higher alcohol intake,
but statistical precision was limited for these estimates.
For both genders, a higher risk was observed among
patients with weight gain >30 kg since age 20 years (for
women aRR 1.4 (95% CI 1.1-1.79); for men aRR 1.4 (95%
CI 1.1-1.8)), and among patients younger than 60 years
(for women, <40 years aRR 1.4 (95% CI 1.0-2.0) and 40-
69 years aRR 1.4 (95% CI 1.1-1.7); for men, <40 years
aRR 1.6 (95% CI 1.0-2.5) and 40-69 years aRR 1.3 (95%
CI 1.0-1.6)) compared to over 60 years.
The sub-analyses, restricting the analysis on patients
with a CRP level of ≤10 mg/L and the analyses restrict-
ing on no previous hospitalization the past 14-days
showed consistent results with the full analysis.
In the linear regression analysis, (Table 2), increasing
fasting blood glucose (adjusted β (Model 3) 0.03 (95% CI
0.006- 0.04)) showed a weak but positive association
with elevated CRP, after adjusting for age, gender, waist
circumference, and other biomarker levels.
Discussion
This study, using cross-sectional baseline data from the
nationwide DD2 cohort and biobank, show that about
40% of newly diagnosed Type 2 DM patients in
Denmark have an elevated CRP level (more than 3 mg/
L). Several potentially modifiable factors, such as lack of
physical activity, weight gain, central obesity, absence of
statin treatment, and high fasting blood glucose are as-
sociated with elevated CRP levels in Type 2 DM, but the
strengths of these associations may vary by gender.
The results from our explorative study provide new
knowledge about CRP levels and associated factors in
Table 1 Lifestyle and clinical factors of 1,037 newly diagnosed T2 DM patients in the Danish population-based DD2



























N (%) N (%) N% N%
Age
Age < 40 years 8 (35) 15(65) 1.73 (1.23-2.43) 1.41 (0.97-2.04) 18 (59) 13 (41) 1.34 (0.89-2.17) 1.61 (1.03-2.52)
Age 40-59 years 84 (46) 98 (54) 1.43 (1.16-1.76) 1.35 (1.09-1.66) 145 (62) 90 (38) 1.26 (1.00-1.59) 1.30 (1.03-1.62)




0 172 (55) 139 (45) 1 1 283 (70) 119 (30) 1 1
1-2 57 (52) 54 (48) 1.10 (0.86-1.37) 1.15 (0.91-1.44) 92 (59) 63 (41) 1.37 (1.0-1.75) 1.47 (1.15-1.89)




No 213 (54) 189 (46) 1 1 307 (69) 139 (31) 1 1
Yes 31 (51) 30 (49) 1.05 (0.79-1.38) 1.18 (0.90-1.56) 81 (57) 61 (43) 1.38 (1.09-1.74) 1.50 (1.17-1.91)
High alcohol
intakeb
No 235 (54) 196 (46) 1 1 347 (65) 183 (35) 1 1
Yes 9 (50) 9 (50) 1.10 (0.68-1.77) 1.20 (0.77-1.87) 41 (70) 17 (30) 0.85 (0.56-1.28) 0.88 (0.59-1.32)
Physical activity
Regular 118 (59) 84 (41) 1 1 146 (75) 48 (25) 1 1
None 126 (51) 121(49) 1.18 (0.96-1.45) 1.14 (0.93-1.40) 242 (61) 142 (39) 1.49 (1.13-1.97) 1.46 (1.11-1.91)
Central obesityc
No 22 (81) 5 (19) 1 1 40 (77) 12 (23) 1 1
Yes 222 (53) 200 (47) 2.55 (1.15-5.68) 2.27 (1.00-5.16) 347 (65) 188 (35) 1.52 (0.91-2.53) 1.42 (0.83-2.41)
Weight gain
>30 kg since
20 years of age
No 164 (61) 103 (39) 1 1 256 (72) 100 (28) 1 1
Yes 80 (44) 102 (56) 1.45 (1.19-1.77) 1.36 (1.11-1.66) 132 (57) 100 (43) 1.54 (1.23-1.92) 1.42 (1.13-1.78)
Antihypertensive
treatment
No 75 (67) 56 (43) 1 1 126 (70) 52 (30) 1 1
Yes 169 (21) 149(47) 1.10 (0.87-1.38) 1.23 (0.97-1.57) 162 (64) 148 (36) 1.63 (1.26-2.11) 1.24 (0.95-1.62)
Statin treatment
No 61 (43) 83 (57) 1 1 124 (64) 66 (35) 1 1
Yes 183 (60) 122 (40) 0.69 (0.57-0.84) 0.75 (0.61-0.91) 264 (66) 134 (34) 0.96 (0.76-1.23) 0.96 (0.41-1.89)
aAdjusted for age, gender, central obesity, comorbidity, physical activity and alcohol consumption (except when stratified by given variable).
bHigh alcohol intake defined as (≥14/21 alcoholic drinks/week for women/men).
cCentral obesity defined as waist circumference ≥94 cm men/≥80 cm women.
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with previous cross-sectional studies of the general
population or persons with prevalent Type 2 DM[5,8,18]. In line with previous evidence in the general
population, we found that central obesity independently
is associated with CRP elevation at Type 2 DM debut
Table 2 Regression analysis of biomarkers and the association with CRP levels in 1037 patients with newly diagnosed























ALATd 0.025 0.06 0.024 0.05 -0.003 -0.009 -0.01 -0.03
(-0.003,0.05) (-0.0006,0.12) (-0.002,0.05) (-0.005,0.11) (-0.03,0.02) (-0.07,0.05) (-0.05, 0.04) (-0.13,0.07)
Amylased -0.019 -0.04 -0.013 -0.03 -0.001 -0.002 0.03 0.06
(-0.048,0.01) (-0.01,-0.06) (-0.04,0.017) (-0.09,0.04) (-0.33, 0.03) (-0.07,0.06) (-0.01, 0.08) (-0.04,0.17)
C-peptided 0.12 0.29 0.12 0.29 0.05 0.0004 0.02 0.07
(0.09-0.14) (0.23,0.35) (0.098,0.14) (0.23-0.35) (0.03,0.07) (-0.05,0.05) (-0.01, 0.06) (-0.02,0.16)
Fasting blood glucosed 0.03 0.19 0.03 0.2 0.03 0.15 0.03 0.14
(0.02,0.04) (0.13,0.24) (0.02,0.04) (0.11,0.23) (0.015-0.04) (0.08,0.21) (0.006, 0.04) (0.03,0.25)
aAdjusted for age and gender.
bAdjusted for age, gender, central obesity.
cAdjusted for age, gender central obesity, all biomarkers (except when stratified by given variable).
dAll biomarkers (including CRP) are log transformed.
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ous knowledge that the contributing effect of adiposity
to elevated CRP levels may be especially relevant for
women compared to men [19]. The causal pathways and
time sequence between elevated CRP levels and central
obesity, insulin resistance, and the metabolic syndrome
are complicated and remain largely unresolved.
We also found that statin treatment was associated
with lower risk of elevated CRP levels, consistent with
previous findings from the general population [5]; pos-
sibly due to the anti-inflammatory effects of statins.
Interestingly, this was only seen for females in our study.
The explanation remains unclear as recent meta-
analyses report that statins work similarly between the
genders [20]. The present results suggest that an anti-
inflammatory effect of statins may be expected particular
among women.
However, there are also some discrepancies between
our study and previous literature. In contrast with obser-
vations in the general population we found that in newly
diagnosed type 2 DM patients, young age at DM debut
was associated with substantially higher prevalence of
CRP than older ages, after controlling for differences in
central obesity and other factors. It is thus possible that
a high degree of systemic inflammation and a tendency
towards early Type 2 DM debut travel together.
The 40% prevalence rate of elevated CRP found in our
population-based sample of incident Type 2 DM pa-
tients in Denmark is similar to levels of elevated CRP
found among Hispanics and African-Americans with in-
cident Type 2 DM in the prospective Multi-Ethnic Study
of Atherosclerosis (40%) [21]. The prevalence is slightly
higher than in previously reported cross-sectional sam-
ples of white/European adults from the general popula-
tion; ranging from 28%-35% [4,5,22] in the adult Spanish
population and the general US population included inthe 1999-2000 National Health and Nutrition Examin-
ation Survey.
Elevated CRP has been associated with increased inci-
dence of subsequent cardiovascular events and cardio-
vascular mortality in Type 2 DM patients [2,23]. For
example, in the WOSCOP study, patients with the meta-
bolic syndrome and elevated CRP had increased cardio-
vascular mortality (RR 2.75 (95% CI, 2.1-3.6)) compared
to patients without the metabolic syndrome and with
low CRP values. While the clinical usefulness of CRP
measurement and causality relative to cardiovascular
events has been questioned [24,25], CPR measurements
may help to identify subgroups of Type 2 DM patients
at higher risk for comorbid disease. Of note, we ob-
served that high CRP level was associated with substan-
tially increased overall comorbidity and with previous
cardiovascular disease mainly among men at time of
Type 2 DM debut. It would also be of interest to exam-
ine the relationship of diabetic microvascular complica-
tions, such as diabetic neuropathy, with CRP elevation,
but reliable information on microvascular complications
was unfortunately not available in our present data. CRP
measurements may also identify Type 2 diabetes patients
for whom treatment of cardiovascular risk factors or dia-
betes may be particularly beneficial. Vepsalainen and
colleagues found that physical activity reduced cardio-
vascular events and mortality only for Type 2 DM pa-
tients with CRP levels above 3 mg/L [26]. For a
subgroup of patients with CRP levels higher than the
median, Strom and colleagues showed that atorvastatin
may slow the decline of beta cell function in patients
with type 1 DM [27].
The main strength of our study is its comprehensive
and detailed assessment of lifestyle, clinical, and bio-
markers based on the DD2 database and biobank, with
close to 100% completeness for these variables.
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clinical information on patients with the Type 2 DM.
Study limitations include its cross-sectional design,
leading to uncertainty about whether increased inflam-
mation and elevated CRP levels precede or follow
clinical and metabolic changes. In addition, as discussed
by Thomsen et al., the DD2 cohort likely represents pa-
tients whose newly diagnosed Type 2 DM is more se-
vere than average in Denmark, as enrolment still relies
much on hospital outpatient clinics [10]. We only have
information of co-morbidities registered in DNRP, re-
quiring in- or out-patient hospital care. Thus, chronic
diseases, taking long time to develop and not requiring
specialized care in the early phases, would not be
captured. The assay, albeit not being a hs-CRP mea-
surement, conveys the same sensitivity as a hs-CPR
measurement.Conclusions
T2DM patients with elevated CRP are likely to benefit
from targeted gender-specific lifestyle interventions
[26,28], for females including weight loss and potentially
statin treatment, while for males, physical activity seems
particularly important. Future prospective follow-up
studies of the DD2 study cohort will increase our under-
standing of how CRP elevation is associated with the
clinical course of Type 2 DM.
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